162 related articles for article (PubMed ID: 14706566)
1. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
Moody TW; Dudek J; Zakowicz H; Walters J; Jensen RT; Petricoin E; Couldrey C; Green JE
Life Sci; 2004 Jan; 74(11):1345-57. PubMed ID: 14706566
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.
Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Eur J Biochem; 1999 Oct; 265(1):449-56. PubMed ID: 10491203
[TBL] [Abstract][Full Text] [Related]
3. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Moody TW; Jensen RT; Fridkin M; Gozes I
J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
[TBL] [Abstract][Full Text] [Related]
4. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
5. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
6. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
[TBL] [Abstract][Full Text] [Related]
7. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
[TBL] [Abstract][Full Text] [Related]
9. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.
Sharma A; Walters J; Gozes Y; Fridkin M; Brenneman D; Gozes I; Moody TW
J Mol Neurosci; 2001 Dec; 17(3):331-9. PubMed ID: 11859929
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents.
Fizanne L; Sigaudo-Roussel D; Saumet JL; Fromy B
J Physiol; 2004 Jan; 554(Pt 2):519-28. PubMed ID: 14578481
[TBL] [Abstract][Full Text] [Related]
11. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1555-60. PubMed ID: 9437716
[TBL] [Abstract][Full Text] [Related]
12. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
13. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
14. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
16. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
Juarranz MG; De Neef P; Robberecht P
Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
[TBL] [Abstract][Full Text] [Related]
18. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
Moreno D; Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 2000 Oct; 21(10):1543-9. PubMed ID: 11068102
[TBL] [Abstract][Full Text] [Related]
19. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor.
Rameshwar P; Gascon P; Oh HS; Denny TN; Zhu G; Ganea D
Exp Hematol; 2002 Sep; 30(9):1001-9. PubMed ID: 12225791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]